Aylward M, Chazot G, Maddock J, Schott B
Presse Med. 1984 Jun 23;13(26):1617-9.
The authors have tested a new preparation of dihydroergotamine (microgranules in a capsule) by comparing the clinical results obtained in 30 patients suffering from morning migraine with the plasma levels of the active substance measured in 8 healthy subjects. The microgranules were administered in doses of 30 mg/24 hours and compared with a similar dose of a dihydroergotamine solution. The close correlation observed between sustained plasma levels and prolonged therapeutic effects indicates a truly programmed delivery of dihydroergotamine by the microgranule preparation.
作者通过比较30例晨起偏头痛患者的临床结果与8名健康受试者体内活性物质的血浆水平，对一种新的双氢麦角胺制剂（胶囊中的微粒）进行了测试。微粒的给药剂量为30毫克/24小时，并与类似剂量的双氢麦角胺溶液进行比较。在持续的血浆水平和延长的治疗效果之间观察到的密切相关性表明，微粒制剂能真正实现双氢麦角胺的程序化给药。
